ANAB240517P22500
- 2.20
- 0.000.00%
AnaptysBio Newsroom
Express News | AnaptysBio Inc : JP Morgan Raises Target Price to $29 From $28
Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)
AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
It's been a mediocre week for AnaptysBio, Inc. (NASDAQ:ANAB) shareholders, with the stock dropping 12% to US$23.41 in the week since its latest quarterly results. Revenues of US$7.2m crushed exp
The Analyst Landscape: 7 Takes On AnaptysBio
In the preceding three months, 7 analysts have released ratings for AnaptysBio (NASDAQ:ANAB), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates their rec
Wedbush Reiterates Outperform on AnaptysBio, Maintains $34 Price Target
Wedbush analyst David Nierengarten reiterates AnaptysBio (NASDAQ:ANAB) with a Outperform and maintains $34 price target.
AnaptysBio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 34.28% Wedbush → $34 Reiterates Outperform → Outperform 04/16/2024 85.62% Leerink Partners → $4
Wedbush Reaffirms Their Buy Rating on AnaptysBio (ANAB)
Buy Rating Affirmed for AnaptysBio Amidst Promising Pipeline and Strategic Financial Positioning
AnaptysBio GAAP EPS of -$1.64 Misses by $0.04
Express News | AnaptysBio Q1 2024 Adj EPS $(1.64) Misses $(1.57) Estimate, Sales $7.180M Beat $3.967M Estimate
AnaptysBio | 10-Q: Quarterly report
Express News | AnaptysBio Q1 Net Income USD -43.936 Million
Express News | AnaptysBio Q1 Operating Expenses USD 49.38 Million
Express News | AnaptysBio Q1 Collaboration Revenue USD 7.179 Million
Express News | AnaptysBio Q1 Income From Operations USD -42.201 Million
AnaptysBio 1Q Loss/Shr $1.64 >ANAB
AnaptysBio 1Q Loss/Shr $1.64 >ANAB
Press Release: Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update -- Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agon
Express News | AnaptysBio Inc - Plans to Out-License Imsidolimab in 2024
Express News | AnaptysBio Inc - With All Patients Having Passed 24 Weeks and Furthest Patient Being Treated Through 92 Weeks, Company Is Concluding Gemini-2 Trial
Express News | AnaptysBio Inc - Imsidolimab Well Tolerated Through End of Study